Thermo Fisher stock nears record after UBS upgrade and upbeat 2026 outlook

Thermo Fisher Scientific stock (ISIN US8835561023) closed at USD 648.43 on the New York Stock Exchange on September 16, 2026, up 1.1% from the prior session and within sight of a new 52-week high that was set intraday at USD 653.40 on the same day, according to data cited by MK.MK This closing level reflects a strong three-month gain of 37.2%, giving the group a market capitalization of USD 239.8 billion as of September 16, 2026.MK For investors, the combination of a buoyant share price and upgraded guidance has turned Thermo Fisher stock into one of the notable large-cap movers in the life sciences sector this month.

UBS upgrade and valuation backdrop

The most conspicuous catalyst for Thermo Fisher stock in mid-September is a rating change from UBS that adds fresh support to the bull case for the shares.Investing.com As Investing.com reports on September 16, 2026, UBS has upgraded Thermo Fisher Scientific from Neutral to Buy and simultaneously raised its price target from USD 540 to USD 730, implying upside of roughly 12.6% from the September 16 closing price of USD 648.43.Investing.com UBS expects Thermo Fisher to return to 5% to 6% organic revenue growth by 2027, accompanied by operating margin expansion and double-digit earnings per share growth, underscoring that the bank sees the recent rally as underpinned by fundamentals rather than purely sentiment.Investing.com

The upgrade comes against the backdrop of a broadly positive analyst stance on Thermo Fisher stock. MarketBeat notes that two analysts currently rate the shares Strong Buy, seventeen assign a Buy rating, five recommend Hold and two rate the stock Sell, resulting in an average rating of Moderate Buy and a consensus price target of USD 624.64.MarketBeat With the shares trading above that consensus level after their recent run, this puts more weight on houses such as UBS that argue the stock can sustain a premium valuation as growth accelerates again.

Raised 2026 outlook after strong second quarter

Beyond the rating action, the operating story has been moving in Thermo Fisher’s favor in recent months. According to a research note from Zacks dated September 17, 2026, Thermo Fisher’s shares have outperformed the Zacks Medical - Instruments industry over the past year, gaining 36.2% versus a 0.5% decline for the sector.Zacks Zacks highlights that management raised its 2026 revenue and adjusted EPS outlook after better-than-expected second-quarter results, signaling greater confidence in the current year trajectory.Zacks

In that context, the Zacks Consensus Estimate now projects 2026 adjusted EPS of USD 25.12 on revenues of USD 47.80 billion for Thermo Fisher, reflecting expectations for solid double-digit earnings growth and mid-single-digit revenue growth in the current year.Zacks Analyst data compiled by Yahoo Finance are broadly consistent, showing average 2026 revenue estimates of USD 47.87 billion and EPS expectations of USD 25.13, with 26 to 27 analysts covering the stock on these measures.Yahoo Finance That sets a quantitative backdrop in which the UBS target implies a forward price to earnings multiple in the high twenties, a level investors will judge against the company’s ability to deliver on its upgraded guidance.

The second quarter itself, which ended in June 2026, is described by Zacks as having come in ahead of internal expectations, prompting the upward revision to the full-year outlook.Zacks While detailed figures for that quarter are not repeated in the latest Zacks note, the commentary emphasizes improving customer activity across end markets, continued share gains and disciplined execution of Thermo Fisher’s growth strategy, including demand from pharma and biotech customers led by bioproduction, clinical research and the research and safety channel.Zacks Against that backdrop, management’s decision to lift guidance suggests that the second quarter performance is viewed internally not as a one-off but as part of a more durable trend.

Consensus expectations and growth narrative

Analyst consensus figures compiled by Yahoo Finance for Thermo Fisher underline the growth narrative that UBS and others are leaning on.Yahoo Finance For the current quarter ending in September 2026, the average revenue estimate stands at USD 11.95 billion, with a range from USD 11.82 billion to USD 12.05 billion, while average EPS is expected at USD 6.41, reflecting year-on-year growth embedded in those forecasts.Yahoo Finance For the following quarter ending in December 2026, consensus revenue rises to USD 12.91 billion with EPS projected at USD 7.26, and for the 2027 fiscal year analysts on average expect revenues of USD 50.33 billion and EPS of USD 27.53.Yahoo Finance

These figures point to a revenue increase of around 5.1% from the 2026 consensus of USD 47.87 billion to the 2027 consensus of USD 50.33 billion, while EPS is projected to grow about 9.5% from USD 25.13 in 2026 to USD 27.53 in 2027.Yahoo Finance That combination of mid-single-digit top-line growth and high-single to low-double-digit earnings growth is broadly consistent with UBS’s expectation of 5% to 6% organic revenue growth by 2027 and sustained margin expansion.Investing.com For shareholders, the key question is whether this projected trajectory can be delivered in an environment of macroeconomic uncertainty and intense competition.

In its September 17 note, Zacks explicitly flags macroeconomic uncertainty, currency volatility, acquisition-related leverage and intense competition as key risks to the story, even as it remains constructive on the company’s strategic positioning.Zacks This balance of bullish earnings projections and acknowledged risk factors suggests that while the recent share price strength is supported by improving fundamentals, the margin for error on execution and capital allocation is shrinking as the valuation multiple stretches.

Order momentum and strategic positioning

Thermo Fisher’s management has been signaling robust order momentum and confidence in the medium-term outlook at recent investor events. A Russian-language analysis from Finmarket, summarizing remarks at the Morgan Stanley healthcare conference in September 2026, notes that top management indicated orders are arriving ahead of expectations across all major business lines and stated that 2026 would be an outstanding year for the business.Finmarket In the same context, the analysis explains that an investment firm has placed its rating and target price for Thermo Fisher under review after the stock delivered 38% returns over the past six months, underscoring how rapidly sentiment has improved.Finmarket

Zacks echoes this positive operational tone, pointing to improving customer activity across all end markets, continued market share gains and disciplined execution of Thermo Fisher’s growth strategy.Zacks It highlights particularly strong demand from pharmaceutical and biotech customers, led by bioproduction and clinical research, as well as contributions from the research and safety channel.Zacks Acquisitions such as Clario and the filtration and separation business are cited as strengthening capabilities and supporting revenue synergies, while new products, AI-enabled workflows and expanded customer collaboration centers are said to reinforce Thermo Fisher’s competitive position.Zacks

This narrative of demand strength and technological investment is consistent with comments attributed to chief executive Marc Casper, who recently told CNBC that AI is shortening the time to market for medicines that are effective and safe, with Thermo Fisher positioned as a key enabler of that trend.Ground News For investors following Thermo Fisher stock, such strategic commentary adds a qualitative layer to the quantitative guidance increases and consensus estimates, suggesting that management sees structural tailwinds as well as cyclical recovery in customer spending.

Next steps and earnings calendar

Looking ahead, analyst pages compiled by Yahoo Finance show that 20 analysts cover Thermo Fisher’s current quarter ending in September 2026, 19 cover the next quarter ending in December 2026 and 26 to 28 cover the full-year 2026 and 2027 estimates, indicating broad institutional attention.Yahoo Finance While a precise date for the next earnings release is not highlighted in the latest analyst overviews, the timing of the current quarter’s end implies that investors will be looking for a third-quarter update in the coming weeks, which will be scrutinized for confirmation that the raised 2026 guidance and UBS’s upgraded target remain well supported.

In the meantime, the broader US equity market has turned more volatile as the Federal Reserve has shifted back toward rate hikes, with major indices seeing notable drops amid concerns about persistent inflation.Sina Finance If financial conditions tighten further, that could test the resilience of growth expectations across the medical instruments and life sciences tools space, including Thermo Fisher. For now, however, the company’s combination of raised guidance, strong demand indicators and supportive analyst actions has kept Thermo Fisher stock trading near its highs even as indices wobble.

Thermo Fisher stock price and valuation snapshot

As of the latest completed trading day on September 16, 2026, Thermo Fisher stock finished at USD 648.43 on the New York Stock Exchange, having set an intraday 52-week high at USD 653.40 during the session and carrying a market capitalization of USD 239.8 billion.MK With the shares up 37.2% over the past three months and more than 36% over the past year versus a slight decline for the broader medical instruments industry,MKZacks Thermo Fisher now trades at levels where future execution on its raised 2026 and 2027 outlook will be critical in sustaining the rally.

More news and analyses on Thermo Fisher Scientific stock